PepGen Inc. ( (PEPG) ) has released its Q4 earnings. Here is a breakdown of the information PepGen Inc. presented to its investors.
PepGen Inc. is a clinical-stage biotechnology company focused on developing next-generation oligonucleotide therapies to treat severe neuromuscular and neurological diseases. The company utilizes its proprietary EDO platform to enhance the delivery and efficacy of these therapies.
In its latest earnings report, PepGen Inc. announced positive initial results from its FREEDOM-DM1 trial, showcasing significant splicing correction in patients with Myotonic Dystrophy Type 1 (DM1). The company also highlighted progress in its CONNECT1-EDO51 trial for Duchenne Muscular Dystrophy (DMD), with full enrollment in the 10 mg/kg cohort and anticipated results in the third quarter of 2025.
Key financial metrics revealed that PepGen ended 2024 with $120.2 million in cash, cash equivalents, and marketable securities, expected to fund operations into 2026. The company reported increased research and development expenses of $76.5 million for the year, reflecting its ongoing commitment to advancing its clinical programs. Despite a net loss of $90.0 million for 2024, the loss per share improved compared to the previous year.
Strategically, PepGen is advancing its clinical trials with expectations to report further results from its FREEDOM and CONNECT1 studies in 2025. The company is also addressing regulatory queries from Health Canada and the FDA to ensure the continuation and expansion of its clinical trials.
Looking ahead, PepGen remains focused on achieving key data milestones and advancing its investigational therapies through clinical development. The management is optimistic about the potential of its EDO platform to deliver transformative treatments for patients with severe diseases.